[1] 郭立杰,王艳,王敏,等. 国产恩替卡韦治疗慢性乙型肝炎患者早期抗病毒疗效观察. 实用肝脏病杂志,2017,20(2):226-227. [2] 朱朝敏,杨先涛. 乙型肝炎疫苗预防母婴传播的方法与效果. 实用肝脏病杂志,2012,15(6):487-489. [3] Thio CL,Guo N,Xie C,et al.Global elimination of mother-to-child transmission of hepatitis B:revisiting the current strategy. Lancet Infect Dis,2015,15(8):981-985. [4] Lou H,Ding W,Dong M,et al.The presence of hepatitis B surface antigen in the ova of pregnant women and its relationship with intra-uterine infection by hepatitis B virus. J Int Med Res,2010,38(1):214-219. [5] Wang Z,Zhang J,Yang H,et al.Quantitative analysis of HBV DNA level and HBeAg titer in hepatitis B surface antigen positive mothers and their babies:HBeAg passage through the placenta and the rate of decay in babies. J Med Virol,2003,71(3):360-366. [6] 王敏芝. 乙型肝炎病毒携带产妇感染状态与新生儿母婴传播的相关性研究. 中国妇幼保健,2017,32(11):2360-2363. [7] Sun KX,Li J,Zhu FC,et al.A predictive value of quantitative HBsAg for serum HBV DNA level among HBeAg-positive pregnant women. Vaccine,2012,30(36):5335-5340. [8] Shao Q,Zhao X,Yao Li MD.Role of peripheral blood mononuclear cell transportation from mother to baby in HBV intrauterine infection.Arch Gynecol Obstet,2013,288(6):1257-1261. [9] Wu Q, Huang H,Sun X,et al.Telbivudine prevents vertical transmission of hepatitis B virus from women with high viral loads:a prospective long-term study. Clin Gastroenterol Hepatol,2015,13(6):1170-1176. |